RedPath Executes Agreement with MultiPlan Preferred Provider Network
PITTSBURGH--(BUSINESS WIRE)--RedPath Integrated Pathology, Inc., a leader in molecular diagnostics, has executed an agreement with MultiPlan, Inc., one of the nation’s largest healthcare preferred provider organization (PPO) networks. The agreement increases the total number of covered lives for RedPath’s patented PathFinderTG® test for pancreatic cancer to more than 74 million people.
“RedPath now has a total of seven contracted agreements with national PPO providers, and will continue to work with payors to expand patient access to our PathFinderTG test”
“RedPath now has a total of seven contracted agreements with national PPO providers, and will continue to work with payors to expand patient access to our PathFinderTG test,” said Dennis M. Smith, Jr., M.D., president and chief executive officer of RedPath Integrated Pathology.
“As use of our test gains adoption with physicians, insurance providers are recognizing the importance PathFinderTG has on improving patient care while decreasing healthcare costs,” added Dr. Smith.
The MultiPlan Network is a nationwide complementary provider network. Just as the name implies, the MultiPlan Network adds to the coverage of a primary PPO or a HMO/POS/EPO network by giving health plan participants an additional choice of providers at discounted rates.
MultiPlan created the complementary network concept in 1980, recognizing the emerging trend toward multi-sited workforces and a growing mobility of health plan participants. Nearly 5,000 hospitals, 100,000 ancillary facilities and 730,000 healthcare professionals participate from all states.
About RedPath Integrated Pathology
RedPath Integrated Pathology, Inc. is a Pittsburgh-based molecular diagnostics laboratory focused on providing novel solutions for clinicians. RedPath’s patented PathFinderTG® platform produces mutational profiles to help physicians resolve complex diagnostic dilemmas in patients who are at risk of cancer. RedPath performs all clinical testing and R&D in its state-of-the-art, CLIA-certified and CAP-accredited laboratory.
The PathFinderTG platform is supported by more than 20 years of scientific and clinical research, and studies using it have been published in more than 200 peer-reviewed journals, including The New England Journal of Medicine. Based on the strong clinical data supporting this platform, RedPath has received positive coverage decisions from Medicare and private payers. For more information about RedPath Integrated Pathology visit www.redpathip.com or contact Andrew Mignatti at 412-224-6100.